高流量鼻导管氧疗用于急诊儿童哮喘的初步临床试验
这项前瞻性随机预试验纳入62例1-14岁中重度哮喘急性发作患儿,比较经鼻高流量氧疗(HFNC)与常规氧疗。结果显示,治疗2小时内HFNC组肺评分(PS)下降≥2分的比例显著高于对照组(53% vs 28%,P=.01),但两组在转归、住院时长及额外治疗需求上无显著差异,且未报告副作用。
要点
- 中重度哮喘急性发作患儿经一线治疗仍存在呼吸窘迫时,HFNC可能较常规氧疗更快速缓解症状。
- HFNC组2小时内PS下降≥2分者占53%,常规氧疗组占28%,差异有统计学意义(P=.01)。
- 两组转归、住院时长及额外治疗需求无显著差异,未报告副作用。
核心结论
- 对于一线治疗难以控制的中重度哮喘急性发作患儿,HFNC在治疗最初2小时内减少呼吸窘迫方面似乎优于常规氧疗。
- 仍需进一步研究证实HFNC在急诊哮喘及呼吸衰竭管理中的整体疗效。
研究设计与样本
- 前瞻性随机预试验,2012年9月至2015年12月在三级学术儿科急诊开展。
- 纳入1-14岁中重度哮喘急性发作患儿,初始治疗(沙丁胺醇/异丙托溴铵及糖皮质激素)后肺评分(PS)≥6或面罩吸氧下血氧饱和度<94%者随机分组。
- 共随机分配62例患儿至HFNC组(n=30)或常规氧疗组(n=32),药物治疗由主治医师决定。
- 主要结局为最初2小时内PS下降≥2分;次要结局包括转归、住院时长及额外治疗需求。
主要发现
- 治疗2小时时,HFNC组有16例(53%)PS下降≥2分,常规氧疗组有9例(28%),组间差异P=.01。
- 两组在转归、住院时长及额外治疗需求方面差异无统计学意义。
- 未报告副作用。
关键数值与推荐
- 纳入标准:肺评分(PS)≥6或面罩吸氧下血氧饱和度<94%,且经初始沙丁胺醇/异丙托溴铵及糖皮质激素治疗。
- 主要结局判定:开始治疗后2小时内PS下降≥2分。
临床怎么用
- 对于急诊中重度哮喘急性发作且一线治疗反应不佳的患儿,可考虑使用HFNC以快速缓解呼吸窘迫。
- HFNC对转归、住院时长及额外治疗需求的影响尚不明确,需结合临床综合判断。
局限性
- 本研究为预试验,样本量较小(共62例)。
- 药物治疗由主治医师决定,可能存在混杂。
- 需进一步研究证实HFNC的整体疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy of high-flow nasal cannula (HFNC) oxygen therapy and safety in children with asthma and moderate respiratory failure in the emergency department (ED). STUDY DESIGN: This was a prospective randomized pilot trial of children (aged 1-14 years) presenting to a tertiary academic pediatric ED with moderate-to-severe asthma exacerbations between September 2012 and December 2015. Patients with a pulmonary score (PS) ≥6 or oxygen saturation <94% with a face mask despite initial treatment (salbutamol/ipratropium bromide and corticosteroids) were randomized to HFNC or to conventional oxygen therapy. Pharmacologic treatment was at the discretion of attending physicians. The primary outcome was a decrease in PS ≥2 in the first 2 hours. Secondary outcomes included disposition, length of stay, and need for additional therapies. RESULTS: We randomly allocated 62 children to receive either HFNC (n = 30) or standard oxygen therapy (n = 32). Baseline patient characteristics were similar in the 2 groups. At 2 hours after the start of therapy, PS had decreased by ≥2 points in 16 patients in the HFNC group (53%) compared with 9 controls (28%) (P = .01). Between-group differences in disposition, length of stay, and need for additional therapies were not significant. No side effects were reported. CONCLUSION: HFNC appears to be superior to conventional oxygen therapy for reducing respiratory distress within the first 2 hours of treatment in children with moderate-to-severe asthma exacerbation refractory to first-line treatment. Further studies are needed to demonstrate its overall efficacy in the management of asthma and respiratory failure in the ED. TRIAL REGISTRATION: EudraCT: 2012-001771-36.
引用
- Ballestero Y, De Pedro J, Portillo N, et al. Pilot Clinical Trial of High-Flow Oxygen Therapy in Children with Asthma in the Emergency Service. J Pediatr. 2018. PMID: 29331328. doi:10.1016/j.jpeds.2017.10.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。